Source link : https://www.newshealth.biz/health-news/most-targeted-cancer-drugs-lack-substantial-clinical-benefit/
TOPLINE: An analysis of molecular-targeted cancer drug therapies recently approved in the United States found that fewer than one third demonstrated substantial clinical benefits at the time of approval. METHODOLOGY: The strength and quality of evidence supporting genome-targeted cancer drug approvals vary. A big reason is the growing number of cancer drug approvals based on […]
Author : News Health
Publish date : 2024-04-16 13:14:43
Copyright for syndicated content belongs to the linked Source.